Effects of glycemic indicators on early neurological outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis

Table 1 Baseline characteristics of patients with acute ischemic stroke, mean ± standard deviation, n (%)

Characteristics	Admission hyperglycemia, n = 329	Without admission hyperglycemia, n = 490	P value
Age in years	68.47 ± 11.85	67.30 ± 11.84	0.165
Female	124 (37.7)	169 (34.5)	0.349
Coronary heart disease	53 (16.1)	70 (14.3)	0.474
Smoking	112 (34.0)	173 (35.3)	0.710
Drinking	84 (25.5)	127 (25.9)	0.901
Atrial fibrillation	59 (17.9)	78 (15.6)	0.449
History of TIA-S	77 (23.4)	104 (21.2)	0.461
Hypertension	218 (66.3)	288 (58.8)	0.031
Diabetes mellitus	149 (45.3)	129 (26.3)	< 0.001
Initial NIHSS, median (IQR)	9 (4, 14)	7 (4, 12)	< 0.001
Stroke subtype			0.076
Large artery atherosclerosis	116 (35.3)	157 (32.0)
Small artery disease	122 (37.1)	208 (42.4)
Cardioembolism	54 (16.4)	56 (11.4)
Others	37 (11.2)	69 (14.1)
Systolic blood pressure in mmHg	157.42 ± 23.65	156.59 ± 24.25	0.628
Diastolic blood pressure in mmHg	90.36 ± 15.03	90.94 ± 13.04	0.553
White blood cell counts as × 109	8.59 ± 3.04	8.26 ± 2.91	0.114
Platelets as × 109	208.49 ± 61.80	208.19 ± 59.92	0.945
Activated partial thromboplastin time in seconds	32.57 ± 7.95	32.85 ± 4.72	0.529
Prothrombin time in seconds	14.89 ± 17.33	14.27 ± 16.27	0.602
Total cholesterol in mmol/L	4.27 ± 1.62	4.16 ± 1.28	0.275
Triglyceride in mmol/L	1.71 ± 2.95	1.61 ± 3.43	0.669
Low-density lipoprotein in mmol/L	2.92 ± 1.01	2.80 ± 0.86	0.087
High-density lipoprotein in mmol/L	1.20 ± 0.44	1.22 ± 0.40	0.453
Door-to-needle treatment in minutes	33.14 ± 21.15	31.97 ± 20.46	0.430
Onset-to-treatment in minutes	146.83 ± 50.87	142.02 ± 49.12	0.176

IQR: Interquartile range; NIHSS: National Institutes of Health Stroke Scale; TIA-S: Transient ischemic attack and/or stroke.